https://ars-pharma.com/2018/12/19/ars-pharmaceuticals-advances-clinical-program-for-intranasal-epinephrine-spray/2022-11-09T09:32:07-08:00https://ars-pharma.com/2019/02/19/ars-pharmaceuticals-announces-fda-fast-track-designation-for-ars-1-intranasal-epinephrine-spray/2022-11-09T09:32:07-08:00https://ars-pharma.com/2019/06/04/ars-pharmaceuticals-announces-results-from-epi-04-clinical-study-of-ars-1-intranasal-epinephrine-spray-in-allergy-patients-with-allergic-rhinitis/2022-11-09T09:32:07-08:00https://ars-pharma.com/2019/06/18/ars-pharmaceuticals-announces-the-appointment-of-two-new-board-members/2022-11-09T09:32:07-08:00https://ars-pharma.com/2020/03/02/ars-pharmaceuticals-to-present-new-data-from-neffy-ars-1-studies-at-aaaai-2020-annual-meeting/2022-11-09T09:32:07-08:00https://ars-pharma.com/2020/03/18/new-data-from-neffytm-ars-1-studies-profiled-by-aaaai/2022-11-09T09:32:07-08:00https://ars-pharma.com/2020/07/13/ars-pharmaceuticals-announces-new-patent-on-ars-1-epinephrine-nasal-spray/2022-11-09T09:32:07-08:00https://ars-pharma.com/2020/09/22/ars-pharmaceuticals-and-recordati-announce-exclusive-license-for-the-rights-in-europe-and-additional-countries-for-neffytm-ars-1-epinephrine-nasal-spray/2022-11-09T09:32:07-08:00https://ars-pharma.com/2020/11/30/ars-announces-acceptance-of-market-authorization-application-submission-to-european-medicines-agency-for-neffy-ars-1-epinephrine-nasal-spray/2022-11-09T09:32:07-08:00https://ars-pharma.com/2021/05/13/ars-pharmaceuticals-strengthens-board-of-directors-with-appointment-of-industry-leader-and-innovator-brent-saunders/2022-11-09T09:32:07-08:00https://ars-pharma.com/2021/08/31/ars-pharmaceuticals-raises-55-million-in-series-d-funding-for-launch-preparations-of-neffy-epinephrine-nasal-spray/2022-11-09T09:32:07-08:00https://ars-pharma.com/2022/02/02/ars-pharmaceuticals-inc-to-share-new-data-at-the-2022-american-academy-of-allergy-asthma-immunology-aaaai-annual-meeting/2022-11-09T09:32:07-08:00https://ars-pharma.com/2022/02/09/ars-pharmaceuticals-expands-executive-leadership-team-with-addition-of-pharmaceutical-commercialization-veterans/2022-11-09T09:32:07-08:00https://ars-pharma.com/2022/04/20/ars-pharmaceuticals-appoints-eric-karas-as-chief-commercial-officer-and-kathleen-scott-as-chief-financial-officer/2022-11-09T09:32:07-08:00https://ars-pharma.com/2022/07/21/silverback-therapeutics-and-ars-pharmaceuticals-announce-merger/2022-11-09T09:32:07-08:00https://ars-pharma.com/2022/07/21/silverback-therapeutics-and-ars-pharmaceuticals-conference-call/2022-11-09T09:32:07-08:00https://ars-pharma.com/2022/10/21/ars-pharmaceuticals-announces-fda-acceptance-of-nda-for-neffy-epinephrine-nasal-spray-for-the-treatment-of-allergic-reactions-type-i-including-anaphylaxis/2022-11-09T09:32:07-08:00https://ars-pharma.com/2022/11/08/ars-pharmaceuticals-closes-merger-with-silverback-therapeutics/2022-11-08T12:50:29-08:00https://ars-pharma.com/2022/11/10/ars-pharmaceuticals-announces-presentation-of-clinical-data-supporting-neffy-epinephrine-nasal-spray-for-the-treatment-of-allergic-reactions-type-i-including-anaphylaxis/2022-11-10T05:00:16-08:00